pfizer china - Search News

News

Pfizer Strikes Deal With China's 3SBio

Reuters on MSN · 2d

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Yahoo Finance · 2d

Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc. for the development, production, and commercialization of a potential cancer treatment.

Investopedia on MSN · 1d

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Key Takeaways Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe.Chinese firm 3SBio is developing a drug that is in trials to treat several forms of cancer,

Fierce Biotech1d

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results